Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Rigel Pharmaceuticals's current 3-Year Share Buyback Ratio was -1.80%.
The historical rank and industry rank for Rigel Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:
FRA:RI2'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -69.7 Med: -17.7 Max: -0.9
Current: -1.8
During the past 13 years, Rigel Pharmaceuticals's highest 3-Year Share Buyback Ratio was -0.90%. The lowest was -69.70%. And the median was -17.70%.
FRA:RI2's 3-Year Share Buyback Ratio is ranked better than 78.91% of 1190
companies
in the Biotechnology industry
Industry Median: -11.75
vs FRA:RI2: -1.80
Rigel Pharmaceuticals (FRA:RI2) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Rigel Pharmaceuticals 3-Year Share Buyback Ratio Related Terms
FRA:RI2 vs SGP, OCS, GYRE: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's 3-Year Share Buyback Ratio falls into.
Rigel Pharmaceuticals 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -1.80 mean?
Rigel Pharmaceuticals (FRA:RI2) has a 3-Year Share Buyback Ratio of -1.80 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #251 out of 1190 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Rigel Pharmaceuticals' 3-Year Share Buyback Ratio too high?
Rigel Pharmaceuticals' current 3-Year Share Buyback Ratio is -1.80. Based on the distribution chart, Rigel Pharmaceuticals ranks #251 out of 1190 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' 3-Year Share Buyback Ratio compare to SGP and OCS?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #251 out of 1190 companies for 3-Year Share Buyback Ratio. This places Rigel Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current 3-Year Share Buyback Ratio is -1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (FRA:RI2) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.92, compared to a current price of €37.56 — trading 71.4% above its estimated fair value. The current 3-Year Share Buyback Ratio is -1.80. Rigel Pharmaceuticals' overall GF Score™ is 24/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current 3-Year Share Buyback Ratio is -1.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €37.56 is trading 71.4% above its estimated GF Value™ of €21.92.
GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:RI2:
3-Year Share Buyback Ratio: -1.80
GF Value™: €21.92 vs. price of €37.56 (71.4% above fair value)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
24GF Score
Get the complete analysis for FRA:RI2
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
